LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

Search

Ionis Pharmaceuticals Inc

Închisă

SectorSănătate

72.33 0.11

Rezumat

Modificarea prețului

24h

Curent

Minim

71.65

Maxim

73.28

Indicatori cheie

By Trading Economics

Venit

-100M

-229M

Vânzări

46M

203M

Marjă de profit

-112.808

Angajați

1,402

EBITDA

4.7B

4.6B

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+32.07% upside

Dividende

By Dow Jones

Următoarele câștiguri

29 apr. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-1.3B

12B

Deschiderea anterioară

72.22

Închiderea anterioară

72.33

Sentimentul știrilor

By Acuity

50%

50%

156 / 351 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Neutral Evidence

Ionis Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

17 mar. 2026, 22:42 UTC

Câștiguri

Prudential PLC 2025 Adjusted Operating Profit Rises

17 mar. 2026, 21:40 UTC

Câștiguri

Alimentation Couche-Tard Records Higher Profit, Revenue in 3Q

17 mar. 2026, 23:56 UTC

Market Talk

BHP's Next CEO Likely to Build On Existing Strategic Direction -- Market Talk

17 mar. 2026, 23:46 UTC

Market Talk

Nikkei May Rise After Recent Selloffs -- Market Talk

17 mar. 2026, 23:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 mar. 2026, 23:42 UTC

Market Talk

RBA's Return to Policy Tightening Will Work -- Market Talk

17 mar. 2026, 23:38 UTC

Market Talk

Gold Edges Lower on Possible Position Adjustments Before FOMC Decision -- Market Talk

17 mar. 2026, 23:24 UTC

Market Talk

Global Energy Roundup: Market Talk

17 mar. 2026, 23:24 UTC

Market Talk

New Woodside CEO Seen as Low-Risk Appointment -- Market Talk

17 mar. 2026, 22:22 UTC

Market Talk

BHP Hands Reins to Growth-Focused Executive -- Market Talk

17 mar. 2026, 22:20 UTC

Câștiguri

Prudential PLC 2025 New Business Profit $2.78B Vs. $2.46B >2378.HK

17 mar. 2026, 22:20 UTC

Câștiguri

Prudential PLC 2025 Adj Operating Profit $3.31B Vs. $3.13B >2378.HK

17 mar. 2026, 22:07 UTC

Câștiguri

Nvidia Says It Is Restarting Production of AI Chips for Sale in China -- WSJ

17 mar. 2026, 22:05 UTC

Câștiguri

ZTO Express (Cayman): Frank Zhen Wei to Resign From Board

17 mar. 2026, 22:04 UTC

Câștiguri

ZTO Express (Cayman): Board Approves Repurchase of Up to $1.5B of Shares Over Next 24 Months >ZTO

17 mar. 2026, 22:03 UTC

Câștiguri

ZTO Express (Cayman) Raises Semiannual Dividend to 39c Vs. 30c >ZTO

17 mar. 2026, 22:01 UTC

Câștiguri

ZTO Express (Cayman) 4Q Adj EPS 47c >ZTO

17 mar. 2026, 22:01 UTC

Câștiguri

ZTO Express (Cayman) 4Q Rev $2.08B >ZTO

17 mar. 2026, 22:01 UTC

Câștiguri

ZTO Express (Cayman) 4Q EPS 47c >ZTO

17 mar. 2026, 21:26 UTC

Câștiguri

Oklo Stock Wavers After Earnings, but the Nuclear Start-Up Has Good News -- Barrons.com

17 mar. 2026, 21:09 UTC

Câștiguri

Couche-Tard: 12 Company-Operated Stores Acquired During 3Q

17 mar. 2026, 21:08 UTC

Câștiguri

Couche-Tard 3Q Consolidated Same-Store Merchandise Revenue Up 2% >ATD.T

17 mar. 2026, 21:08 UTC

Câștiguri

Couche-Tard 3Q Adj EPS 81c >ATD.T

17 mar. 2026, 21:07 UTC

Câștiguri

Couche-Tard 3Q EPS 82c >ATD.T

17 mar. 2026, 21:06 UTC

Câștiguri

Couche-Tard 3Q Rev $21.8B >ATD.T

17 mar. 2026, 21:05 UTC

Câștiguri

Couche-Tard 3Q Adj EPS 81c >ATD.T

17 mar. 2026, 21:05 UTC

Câștiguri

Couche-Tard 3Q Rev $21.8B >ATD.T

17 mar. 2026, 21:05 UTC

Câștiguri

Couche-Tard 3Q EPS 82c >ATD.T

17 mar. 2026, 21:05 UTC

Câștiguri

Couche-Tard 3Q Net $757.2M >ATD.T

17 mar. 2026, 20:50 UTC

Market Talk
Evenimente importante

Energy & Utilities Roundup: Market Talk

Comparație

Modificare preț

Ionis Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

32.07% sus

Prognoză pe 12 luni

Medie 95.54 USD  32.07%

Maxim 110 USD

Minim 72 USD

În baza a 14 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruIonis Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

14 ratings

11

Cumpărare

3

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

29.78 / 33.645Suport & Rezistență

Termen scurt

Neutral Evidence

Termen mediu

Very Strong Bullish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

156 / 351 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat